PLATO Trial

Summary: Patients were randomized to ticagrelor versus clopidogrel during acute coronary syndrome. The primary endpoint of composite death from vascular causes, MI or stroke was reduced by ticagrelor. There was no significant difference in major overall bleeding, however there was an increase in non-major bleeding.

Original Publication:

N Engl J Med. 2009 Sep 10;361(11):1045-57. Epub 2009 Aug 30.

Lancet. 2010 Jan 23;375(9711):283-93. Epub 2010 Jan 13.

Eponym: Platelet Inhibition and Patient Outcomes